WO2001055302A2 - Acides nucleiques, proteines et anticorps - Google Patents
Acides nucleiques, proteines et anticorps Download PDFInfo
- Publication number
- WO2001055302A2 WO2001055302A2 PCT/US2001/001240 US0101240W WO0155302A2 WO 2001055302 A2 WO2001055302 A2 WO 2001055302A2 US 0101240 W US0101240 W US 0101240W WO 0155302 A2 WO0155302 A2 WO 0155302A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- seq
- sequence
- polypeptides
- polynucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the sixth column provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).
- a polypeptide having biological activity refers to a polypeptide exhibiting activity similar to, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that ofthe polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide ofthe present invention).
- the PFam database PFam version 5.2, (Sonnhammer et al., Nucl. Acids Res., 26:320-322, (1998)) consists of a series of multiple sequence alignments; one alignment for each protein family. Each multiple sequence alignment is converted into a probability model called a Hidden Markov Model, or HMM, that represents the position-specific variation among the sequences that make up the multiple sequence alignment (see, e.g., R. Durbin et al., Biological sequence analysis: probabilistic models of proteins and nucleic acids, Cambridge University Press, 1998 for the theory of HMMs).
- HMM Hidden Markov Model
- sequence listing may in some instances list only a portion of the DNA sequence in a clone included in the ATCC Deposits, it is well within the ability of one skilled in the art to sequence the DNA mcluded in a clone contained in the ATCC Deposits by use of a sequence (or portion thereof) described in, for example Tables IA or 2 by procedures hereinafter further described, and others apparent to those skilled in the art.
- the present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or the cDNA sequence contained in Clone ID NO:Z.
- the present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X or a complement thereof, a polypeptide encoded by the cDNA contained in Clone ID NO:Z, and/or the polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table IB.
- the invention further includes polypeptide variants which show a functional activity (e.g., biological activity) ofthe polypeptides ofthe invention.
- a functional activity e.g., biological activity
- variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity.
- Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above- described polynucleotides and polypeptides are also encompassed by the invention.
- Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.
- polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table IB and the 5' 10 polynucleotides of another sequence in column 6 are directly contiguous.
- the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table IB is directly contiguous with the 5' 10 polynucleotides of the next sequential exon delineated in Table IB, column 6.
- Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions are also encompassed by the invention.
- Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.
- Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region.
- Representative examples of polypeptide fragments of the invention include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, 281-300, 301-320, 321-340, 341-360, 361-380, 381-400, 401-420, 421-440, 441-460, 461-480, 481-500, 501-520, 521-540, 541-560, 561-580, 581-600, 601-620, 621-640, 641-660, 661-680, 681-700, 701-720, 721-740, 741-760, 761-780,
- amino acid sequence of a polypeptide encoded by a polynucleotide sequence of SEQ ID NO:X may be analyzed using the default parameters of the , DNASTAR computer algorithm (DNASTAR, Inc., 1228 S. Park St., Madison, WI 53715 USA; http://www.dnastar.com/).
- the expression vectors will preferably include at least one selectable marker.
- markers include dihydrofolate reductase, G418 or neomycin resistance, glutamine synthase, for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria.
- Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris (ATCC Accession No.
- the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a Pichea yeast system essentially as described in "Pichia Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998.
- This expression vector allows expression and secretion of a polypeptide of the invention by virtue of the strong AOX1 promoter linked to the Pichia pastoris alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.
- PHO alkaline phosphatase
- a polypeptide of the present invention or fragment or variant thereof is attached to macrocyclic chelators that associate with radiometal ions, including but not limited to, Lu, Y, Ho, and Sm, to polypeptides.
- the radiometal ion associated with the macrocyclic chelators is ⁇ In.
- the radiometal ion associated with the macrocyclic chelator is 90 Y.
- the macrocyclic chelator is 1,4,7, 10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA).
- the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.
- Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found.
- Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different proteins.
- leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize.
- polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., U..S Patent Number 5,478,925, which is herein incorporated by reference in its entirety).
- polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of the invention (e.g., a polypeptide or fragment or variant ofthe amino acid sequence of SEQ ID NO:Y or a polypeptide encoded by the cDNA contained in Clone ID NO:Z, and/or an epitope, ofthe present invention) as determined by immunoassays well known in the art for assaying specific antibody-antigen binding.
- TCR T-cell antigen receptors
- receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described supra).
- antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% ofthe activity in absence ofthe antibody.
- the invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand.
- mice can be immunized with a polypeptide of the invention or a cell expressing such peptide.
- an immune response e.g., antibodies specific for the antigen are detected in the mouse serum
- the mouse spleen is harvested and splenocytes isolated.
- the splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution.
- Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos.
- the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention.
- one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds.
- Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.
- AcNPV is used as a vector to express foreign genes.
- the virus grows in Spodoptera frugiperda cells.
- the antibody coding sequence may be cloned individually into non- essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).
- Adenoviruses are other viral vectors that can be used in gene therapy.
- the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by the presence or absence of an appropriate inducer of transcription.
- polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also Levy et al, Science 228:190 (1985); During et al, Ann. Neurol. 25:351 (1989); Howard et al., J.Neurosurg. 71:105 (1989)).
- the amount of the compound of the invention, which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide ofthe invention can be determined by standard clinical techniques.
- in vitro assays may optionally be employed to help identify optimal dosage ranges.
- the precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided accordmg to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides.
- a kit may include a control antibody that does not react with the polypeptide of interest.
- a kit may include a substantially isolated polypeptide antigen comprising an epitope, which is specifically immunoreactive with at least one anti-polypeptide antigen antibody.
- a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine, which can be detected by flow cytometry).
- the kit may include a recombinantly produced or chemically synthesized polypeptide antigen.
- the polypeptide antigen of the kit may also be attached to a solid support.
- the present invention also provides a method for chromosomal localization which involves (a) preparing PCR primers from the polynucleotide sequences in Table IA and/or Table 2 and SEQ ID NO:X and (b) screening somatic cell hybrids containing individual chromosomes.
- oligonucleotide as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).
- Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide.
- the oligonucleotide described above can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of polypeptide of the present invention antigens.
- the invention provides a method for the specific destruction of colon cells (e.g., aberrant colon cells, colon neoplasm) by administering polypeptides of the invention (e.g., polypeptides encoded by polynucleotides of the invention and/or antibodies) in association with toxins or cytotoxic prodrugs.
- polypeptides of the invention e.g., polypeptides encoded by polynucleotides of the invention and/or antibodies
- the invention provides a method for the specific destruction of tissues/cells corresponding to the library source relating to a polynucleotide sequence of the invention as disclosed in column 7 of Table 1 A by administering polypeptides of the invention in association with toxins or cytotoxic prodrugs.
- neoplastic disorders such as, polyps (e.g., sessile polyp, adenomatous polyp, inflammatory polyps), adenomas (e.g., tubular adenoma, tubovillous adenomas, villous adenoma, Gardner syndrome, Peutz- Jeghers syndrome), hyperplastic, polyposis, villous, pseudopolyps, leiomyomas, carcinoids, lipomas, and angiomas, cancers, such as, rectal cancer, adenocarcinoma, colorectal carcinoma, colon cancer, colon carcinoma, colorectal cancer; colonic diseases); miscellaneous intestinal inflammatory disorders, including acquired immunodeficiency syndrome, HIV enteropathy, transplantation, drug-
- binding activity of a given lot of anti- colon antigen antibody or colon antigen polypeptide may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.
- the retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines.
- packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT- 19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAml2, and DAN cell lines as described in Miller, Human Gene Therapy 1 :5-14 (1990), which is inco ⁇ orated herein by reference in its entirety.
- the vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO 4 precipitation.
- the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.
- the cells are engineered, ex vivo or in vivo, using an adeno-associated virus (AAV).
- AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, N., Curr. Topics in Microbiol. Immunol. 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.
- Gastrointestinal disorders include dysphagia, odynophagia, inflammation of the esophagus, peptic esophagitis, gastric reflux, submucosal fibrosis and stricturing, Mallory-Weiss lesions, leiomyomas, lipomas, epidermal cancers, adeoncarcinomas, gastric retention disorders, gastroenteritis, gastric atrophy, gastric/stomach cancers, polyps of the stomach, autoimmune disorders such as pernicious anemia, pyloric stenosis, gastritis (bacterial, viral, eosinophilic, stress- induced, chronic erosive, atrophic, plasma cell, and Menetrier's), and peritoneal diseases (e.g., chyloperioneum, hemoperitoneum, mesenteric cyst, mesenteric lymphadenitis, mesenteric vascular occlusion, panniculitis, neoplasms, perit
- polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used in one or more of the applications decribed herein, as they may apply to veterinary medicine.
- polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for chronic hypergammaglobulmemia evident in such diseases as monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's disease, related idiopathic monoclonal gammopathies, and plasmacytomas.
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001237944A AU2001237944A1 (en) | 2000-01-31 | 2001-01-17 | Nucleic acids, proteins, and antibodies |
EP01910326A EP1252289A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
Applications Claiming Priority (235)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17906500P | 2000-01-31 | 2000-01-31 | |
US60/179,065 | 2000-01-31 | ||
US18062800P | 2000-02-04 | 2000-02-04 | |
US60/180,628 | 2000-02-04 | ||
US18466400P | 2000-02-24 | 2000-02-24 | |
US60/184,664 | 2000-02-24 | ||
US18635000P | 2000-03-02 | 2000-03-02 | |
US60/186,350 | 2000-03-02 | ||
US18987400P | 2000-03-16 | 2000-03-16 | |
US60/189,874 | 2000-03-16 | ||
US19007600P | 2000-03-17 | 2000-03-17 | |
US60/190,076 | 2000-03-17 | ||
US19812300P | 2000-04-18 | 2000-04-18 | |
US60/198,123 | 2000-04-18 | ||
US20551500P | 2000-05-19 | 2000-05-19 | |
US60/205,515 | 2000-05-19 | ||
US20946700P | 2000-06-07 | 2000-06-07 | |
US60/209,467 | 2000-06-07 | ||
US21488600P | 2000-06-28 | 2000-06-28 | |
US60/214,886 | 2000-06-28 | ||
US21513500P | 2000-06-30 | 2000-06-30 | |
US60/215,135 | 2000-06-30 | ||
US21688000P | 2000-07-07 | 2000-07-07 | |
US21664700P | 2000-07-07 | 2000-07-07 | |
US60/216,880 | 2000-07-07 | ||
US60/216,647 | 2000-07-07 | ||
US21748700P | 2000-07-11 | 2000-07-11 | |
US21749600P | 2000-07-11 | 2000-07-11 | |
US60/217,487 | 2000-07-11 | ||
US60/217,496 | 2000-07-11 | ||
US21829000P | 2000-07-14 | 2000-07-14 | |
US60/218,290 | 2000-07-14 | ||
US22096400P | 2000-07-26 | 2000-07-26 | |
US22096300P | 2000-07-26 | 2000-07-26 | |
US60/220,964 | 2000-07-26 | ||
US60/220,963 | 2000-07-26 | ||
US22521300P | 2000-08-14 | 2000-08-14 | |
US22521400P | 2000-08-14 | 2000-08-14 | |
US22544700P | 2000-08-14 | 2000-08-14 | |
US22526600P | 2000-08-14 | 2000-08-14 | |
US22526800P | 2000-08-14 | 2000-08-14 | |
US22451900P | 2000-08-14 | 2000-08-14 | |
US22575900P | 2000-08-14 | 2000-08-14 | |
US22451800P | 2000-08-14 | 2000-08-14 | |
US22575700P | 2000-08-14 | 2000-08-14 | |
US22526700P | 2000-08-14 | 2000-08-14 | |
US22575800P | 2000-08-14 | 2000-08-14 | |
US22527000P | 2000-08-14 | 2000-08-14 | |
US60/225,759 | 2000-08-14 | ||
US60/225,270 | 2000-08-14 | ||
US60/225,757 | 2000-08-14 | ||
US60/225,214 | 2000-08-14 | ||
US60/225,268 | 2000-08-14 | ||
US60/224,518 | 2000-08-14 | ||
US60/225,266 | 2000-08-14 | ||
US60/224,519 | 2000-08-14 | ||
US60/225,213 | 2000-08-14 | ||
US60/225,758 | 2000-08-14 | ||
US60/225,267 | 2000-08-14 | ||
US60/225,447 | 2000-08-14 | ||
US22627900P | 2000-08-18 | 2000-08-18 | |
US60/226,279 | 2000-08-18 | ||
US22686800P | 2000-08-22 | 2000-08-22 | |
US22668100P | 2000-08-22 | 2000-08-22 | |
US22718200P | 2000-08-22 | 2000-08-22 | |
US60/226,868 | 2000-08-22 | ||
US60/227,182 | 2000-08-22 | ||
US60/226,681 | 2000-08-22 | ||
US22700900P | 2000-08-23 | 2000-08-23 | |
US60/227,009 | 2000-08-23 | ||
US22892400P | 2000-08-30 | 2000-08-30 | |
US60/228,924 | 2000-08-30 | ||
US22934300P | 2000-09-01 | 2000-09-01 | |
US22934500P | 2000-09-01 | 2000-09-01 | |
US22934400P | 2000-09-01 | 2000-09-01 | |
US22928700P | 2000-09-01 | 2000-09-01 | |
US60/229,343 | 2000-09-01 | ||
US60/229,344 | 2000-09-01 | ||
US60/229,287 | 2000-09-01 | ||
US60/229,345 | 2000-09-01 | ||
US22950900P | 2000-09-05 | 2000-09-05 | |
US22951300P | 2000-09-05 | 2000-09-05 | |
US60/229,513 | 2000-09-05 | ||
US60/229,509 | 2000-09-05 | ||
US23043700P | 2000-09-06 | 2000-09-06 | |
US23043800P | 2000-09-06 | 2000-09-06 | |
US60/230,438 | 2000-09-06 | ||
US60/230,437 | 2000-09-06 | ||
US23124400P | 2000-09-08 | 2000-09-08 | |
US23124300P | 2000-09-08 | 2000-09-08 | |
US23124200P | 2000-09-08 | 2000-09-08 | |
US23208000P | 2000-09-08 | 2000-09-08 | |
US23208100P | 2000-09-08 | 2000-09-08 | |
US23141400P | 2000-09-08 | 2000-09-08 | |
US23141300P | 2000-09-08 | 2000-09-08 | |
US60/231,244 | 2000-09-08 | ||
US60/232,080 | 2000-09-08 | ||
US60/232,081 | 2000-09-08 | ||
US60/231,242 | 2000-09-08 | ||
US60/231,243 | 2000-09-08 | ||
US60/231,414 | 2000-09-08 | ||
US60/231,413 | 2000-09-08 | ||
US23196800P | 2000-09-12 | 2000-09-12 | |
US60/231,968 | 2000-09-12 | ||
US23239700P | 2000-09-14 | 2000-09-14 | |
US23240000P | 2000-09-14 | 2000-09-14 | |
US23240100P | 2000-09-14 | 2000-09-14 | |
US23306500P | 2000-09-14 | 2000-09-14 | |
US23306300P | 2000-09-14 | 2000-09-14 | |
US23306400P | 2000-09-14 | 2000-09-14 | |
US23239800P | 2000-09-14 | 2000-09-14 | |
US23239900P | 2000-09-14 | 2000-09-14 | |
US60/233,063 | 2000-09-14 | ||
US60/232,400 | 2000-09-14 | ||
US60/232,401 | 2000-09-14 | ||
US60/233,065 | 2000-09-14 | ||
US60/232,397 | 2000-09-14 | ||
US60/233,064 | 2000-09-14 | ||
US60/232,398 | 2000-09-14 | ||
US60/232,399 | 2000-09-14 | ||
US23422300P | 2000-09-21 | 2000-09-21 | |
US23427400P | 2000-09-21 | 2000-09-21 | |
US60/234,274 | 2000-09-21 | ||
US60/234,223 | 2000-09-21 | ||
US23499700P | 2000-09-25 | 2000-09-25 | |
US23499800P | 2000-09-25 | 2000-09-25 | |
US60/234,998 | 2000-09-25 | ||
US60/234,997 | 2000-09-25 | ||
US23548400P | 2000-09-26 | 2000-09-26 | |
US60/235,484 | 2000-09-26 | ||
US23583600P | 2000-09-27 | 2000-09-27 | |
US23583400P | 2000-09-27 | 2000-09-27 | |
US60/235,834 | 2000-09-27 | ||
US60/235,836 | 2000-09-27 | ||
US23632700P | 2000-09-29 | 2000-09-29 | |
US23636800P | 2000-09-29 | 2000-09-29 | |
US23636700P | 2000-09-29 | 2000-09-29 | |
US23636900P | 2000-09-29 | 2000-09-29 | |
US23637000P | 2000-09-29 | 2000-09-29 | |
US60/236,370 | 2000-09-29 | ||
US60/236,367 | 2000-09-29 | ||
US60/236,368 | 2000-09-29 | ||
US60/236,327 | 2000-09-29 | ||
US60/236,369 | 2000-09-29 | ||
US23703700P | 2000-10-02 | 2000-10-02 | |
US23703800P | 2000-10-02 | 2000-10-02 | |
US23704000P | 2000-10-02 | 2000-10-02 | |
US23703900P | 2000-10-02 | 2000-10-02 | |
US23680200P | 2000-10-02 | 2000-10-02 | |
US60/237,040 | 2000-10-02 | ||
US60/237,039 | 2000-10-02 | ||
US60/236,802 | 2000-10-02 | ||
US60/237,037 | 2000-10-02 | ||
US60/237,038 | 2000-10-02 | ||
US23993500P | 2000-10-13 | 2000-10-13 | |
US23993700P | 2000-10-13 | 2000-10-13 | |
US60/239,935 | 2000-10-13 | ||
US60/239,937 | 2000-10-13 | ||
US24178700P | 2000-10-20 | 2000-10-20 | |
US24178500P | 2000-10-20 | 2000-10-20 | |
US24182600P | 2000-10-20 | 2000-10-20 | |
US24096000P | 2000-10-20 | 2000-10-20 | |
US24180900P | 2000-10-20 | 2000-10-20 | |
US24122100P | 2000-10-20 | 2000-10-20 | |
US24180800P | 2000-10-20 | 2000-10-20 | |
US24178600P | 2000-10-20 | 2000-10-20 | |
US60/241,808 | 2000-10-20 | ||
US60/241,221 | 2000-10-20 | ||
US60/241,787 | 2000-10-20 | ||
US60/240,960 | 2000-10-20 | ||
US60/241,809 | 2000-10-20 | ||
US60/241,786 | 2000-10-20 | ||
US60/241,785 | 2000-10-20 | ||
US60/241,826 | 2000-10-20 | ||
US24461700P | 2000-11-01 | 2000-11-01 | |
US60/244,617 | 2000-11-01 | ||
US24652500P | 2000-11-08 | 2000-11-08 | |
US24653200P | 2000-11-08 | 2000-11-08 | |
US24647500P | 2000-11-08 | 2000-11-08 | |
US24652800P | 2000-11-08 | 2000-11-08 | |
US24647600P | 2000-11-08 | 2000-11-08 | |
US24661100P | 2000-11-08 | 2000-11-08 | |
US24652600P | 2000-11-08 | 2000-11-08 | |
US24652700P | 2000-11-08 | 2000-11-08 | |
US24647400P | 2000-11-08 | 2000-11-08 | |
US24647700P | 2000-11-08 | 2000-11-08 | |
US24661000P | 2000-11-08 | 2000-11-08 | |
US60/246,476 | 2000-11-08 | ||
US60/246,528 | 2000-11-08 | ||
US60/246,478 | 2000-11-08 | ||
US60/246,475 | 2000-11-08 | ||
US60/246,523 | 2000-11-08 | ||
US60/246,477 | 2000-11-08 | ||
US60/246,474 | 2000-11-08 | ||
US60/246,609 | 2000-11-08 | ||
US60/246,613 | 2000-11-08 | ||
US60/246,611 | 2000-11-08 | ||
US60/246,527 | 2000-11-08 | ||
US60/246,525 | 2000-11-08 | ||
US60/246,526 | 2000-11-08 | ||
US60/246,610 | 2000-11-08 | ||
US60/246,524 | 2000-11-08 | ||
US60/246,532 | 2000-11-08 | ||
US60/249,300 | 2000-11-17 | ||
US60/249,216 | 2000-11-17 | ||
US60/249,299 | 2000-11-17 | ||
US60/249,215 | 2000-11-17 | ||
US60/249,297 | 2000-11-17 | ||
US60/249,213 | 2000-11-17 | ||
US60/249,214 | 2000-11-17 | ||
US60/249,245 | 2000-11-17 | ||
US60/249,218 | 2000-11-17 | ||
US60/249,212 | 2000-11-17 | ||
US60/249,244 | 2000-11-17 | ||
US60/249,207 | 2000-11-17 | ||
US60/249,208 | 2000-11-17 | ||
US60/249,265 | 2000-11-17 | ||
US60/249,209 | 2000-11-17 | ||
US60/249,217 | 2000-11-17 | ||
US60/249,264 | 2000-11-17 | ||
US60/249,211 | 2000-11-17 | ||
US60/249,210 | 2000-11-17 | ||
US60/250,160 | 2000-12-01 | ||
US60/250,391 | 2000-12-01 | ||
US60/251,988 | 2000-12-05 | ||
US60/251,030 | 2000-12-05 | ||
US60/256,719 | 2000-12-05 | ||
US60/251,479 | 2000-12-06 | ||
US60/251,989 | 2000-12-08 | ||
US60/251,856 | 2000-12-08 | ||
US60/251,868 | 2000-12-08 | ||
US60/251,869 | 2000-12-08 | ||
US60/251,990 | 2000-12-08 | ||
US60/254,097 | 2000-12-11 | ||
US60/259,678 | 2001-01-05 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001055302A2 true WO2001055302A2 (fr) | 2001-08-02 |
WO2001055302A8 WO2001055302A8 (fr) | 2001-09-07 |
WO2001055302A3 WO2001055302A3 (fr) | 2002-02-14 |
Family
ID=27587117
Family Applications (48)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/001321 WO2001055312A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001312 WO2001054733A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001345 WO2001055325A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001357 WO2001055208A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001332 WO2001055318A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001313 WO2001055200A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001359 WO2001055328A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001341 WO2001055322A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001342 WO2001059064A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001335 WO2001055319A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001325 WO2001055202A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001356 WO2001055173A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001315 WO2001055311A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001309 WO2001055308A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001333 WO2001055448A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001355 WO2001055207A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001324 WO2001055314A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001314 WO2001055310A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001352 WO2001055327A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001310 WO2001055387A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001336 WO2001055204A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001311 WO2001055309A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001343 WO2001055323A2 (fr) | 2000-01-31 | 2001-01-17 | Acides ncleiques, proteines et anticorps |
PCT/US2001/001338 WO2001055367A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et antigenes |
PCT/US2001/001326 WO2001055315A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines, et anticorps |
PCT/US2001/001239 WO2001055301A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001322 WO2001055343A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001308 WO2001055364A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucléiques, protéines et anticorps |
PCT/US2001/001349 WO2001054474A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001306 WO2001055307A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001348 WO2001055368A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001350 WO2001055350A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001316 WO2001054473A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001240 WO2001055302A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001328 WO2001055316A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001317 WO2001055201A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001330 WO2001055447A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucléiques, proteines et anticorps |
PCT/US2001/001344 WO2001055324A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001302 WO2001055304A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001337 WO2001055205A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001351 WO2001055355A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001301 WO2001055303A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001353 WO2001055206A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001339 WO2001055320A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001358 WO2001055163A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines, et anticorps |
PCT/US2001/001340 WO2001055321A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001327 WO2001055203A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001354 WO2001057182A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
Family Applications Before (33)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/001321 WO2001055312A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001312 WO2001054733A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001345 WO2001055325A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001357 WO2001055208A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001332 WO2001055318A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001313 WO2001055200A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001359 WO2001055328A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001341 WO2001055322A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001342 WO2001059064A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001335 WO2001055319A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001325 WO2001055202A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001356 WO2001055173A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001315 WO2001055311A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001309 WO2001055308A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001333 WO2001055448A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001355 WO2001055207A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001324 WO2001055314A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001314 WO2001055310A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001352 WO2001055327A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001310 WO2001055387A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001336 WO2001055204A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001311 WO2001055309A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001343 WO2001055323A2 (fr) | 2000-01-31 | 2001-01-17 | Acides ncleiques, proteines et anticorps |
PCT/US2001/001338 WO2001055367A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et antigenes |
PCT/US2001/001326 WO2001055315A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines, et anticorps |
PCT/US2001/001239 WO2001055301A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001322 WO2001055343A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001308 WO2001055364A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucléiques, protéines et anticorps |
PCT/US2001/001349 WO2001054474A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001306 WO2001055307A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001348 WO2001055368A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001350 WO2001055350A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001316 WO2001054473A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
Family Applications After (14)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/001328 WO2001055316A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001317 WO2001055201A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001330 WO2001055447A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucléiques, proteines et anticorps |
PCT/US2001/001344 WO2001055324A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001302 WO2001055304A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001337 WO2001055205A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001351 WO2001055355A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001301 WO2001055303A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001353 WO2001055206A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001339 WO2001055320A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001358 WO2001055163A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines, et anticorps |
PCT/US2001/001340 WO2001055321A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001327 WO2001055203A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
PCT/US2001/001354 WO2001057182A2 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
Country Status (3)
Country | Link |
---|---|
AU (16) | AU2001241409A1 (fr) |
CA (37) | CA2395724A1 (fr) |
WO (48) | WO2001055312A2 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1157038A4 (fr) * | 1999-02-26 | 2005-01-19 | Smithkline Beecham Corp | Clonage du recepteur 7tm (axor 17) du type p2y |
US6893818B1 (en) | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
US7838491B2 (en) | 2001-11-14 | 2010-11-23 | Northwestern University | Self-assembly and mineralization of peptide-amphiphile nanofibers |
US7851445B2 (en) | 2005-03-04 | 2010-12-14 | Northwestern University | Angiogenic heparin-binding epitopes, peptide amphiphiles, self-assembled compositions and related methods of use |
US8063014B2 (en) | 2002-02-15 | 2011-11-22 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
US8076295B2 (en) | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
US8124583B2 (en) | 2002-11-12 | 2012-02-28 | Northwestern University | Composition and method for self-assembly and mineralization of peptide-amphiphiles |
US8138140B2 (en) * | 2003-12-05 | 2012-03-20 | Northwestern University | Self-assembling peptide amphiphiles and related methods for growth factor delivery |
US8450271B2 (en) | 2009-04-13 | 2013-05-28 | Northwestern University | Peptide-based scaffolds for cartilage regeneration and methods for their use |
Families Citing this family (261)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7579160B2 (en) | 1998-03-18 | 2009-08-25 | Corixa Corporation | Methods for the detection of cervical cancer |
US7258860B2 (en) | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6960570B2 (en) | 1998-03-18 | 2005-11-01 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6706262B1 (en) | 1998-03-18 | 2004-03-16 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
AU740405B2 (en) | 1998-05-15 | 2001-11-01 | Genentech Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
US6929938B2 (en) | 2001-08-15 | 2005-08-16 | Millennium Pharmaceuticals, Inc. | 25501, a human transferase family member and uses therefor |
US7141417B1 (en) | 1999-02-25 | 2006-11-28 | Thomas Jefferson University | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene |
JP2003508011A (ja) * | 1999-02-25 | 2003-03-04 | トマス・ジエフアーソン・ユニバーシテイ | ヒトfez1遺伝子である新規ガン抑制遺伝子に関する組成物、キットおよび方法 |
CA2365238A1 (fr) * | 1999-03-23 | 2000-09-28 | Human Genome Sciences, Inc. | 48 proteines humaines secretees |
WO2000058480A1 (fr) * | 1999-03-29 | 2000-10-05 | Kansai Technology Licensing Organization Co., Ltd. | Nouvelle cytidine desaminase |
EP1637541B1 (fr) * | 1999-09-01 | 2010-03-03 | Genentech, Inc. | Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci |
EP1228090A4 (fr) * | 1999-10-27 | 2003-01-22 | Millennium Pharm Inc | Nouvelles molecules de la famille des proteines se rapportant aux card et leurs utilisations |
US7005499B1 (en) * | 1999-11-18 | 2006-02-28 | Genentech, Inc. | Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same |
EP1878795A3 (fr) * | 1999-11-30 | 2008-01-23 | Genentech, Inc. | Compositions et procédés pour le traitement de maladies liées au système immunitaire |
EP1690872A3 (fr) * | 1999-12-01 | 2006-08-23 | Genentech, Inc. | Composition et procédés de diagnostic de tumeurs |
CN1300781A (zh) * | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽-人shc蛋白43和编码这种多肽的多核苷酸 |
US20040043397A1 (en) | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
ES2360155T3 (es) | 2000-01-26 | 2011-06-01 | Agensys, Inc. | 84p2a9: una proteína específica de próstata y testículos altamente expresada en el cáncer de próstata. |
US6953682B2 (en) | 2000-02-10 | 2005-10-11 | Millennium Pharmaceuticals, Inc. | Nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and atpase-like molecules and uses therefor |
US7078205B2 (en) | 2000-02-17 | 2006-07-18 | Millennium Pharmaceuticals, Inc. | Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor |
US20020082212A1 (en) * | 2000-07-20 | 2002-06-27 | Millennium Pharmaceuticals, Inc. | 7716, a novel human ATPase and uses therefor |
US20020090705A1 (en) * | 2000-07-14 | 2002-07-11 | Rachel Meyers | 62088, a novel human nucleoside phosphatase family member and uses thereof |
US20020031815A1 (en) * | 2000-06-26 | 2002-03-14 | Millennium Pharmaceuticals, Inc. | 46619, a novel human beta-ketoacyl synthase and uses thereof |
US20020055159A1 (en) * | 2000-06-15 | 2002-05-09 | Meyers Rachel A. | 23680,a novel human aminotransferase and uses therefor |
US7718397B2 (en) | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
EP1268791A2 (fr) * | 2000-03-23 | 2003-01-02 | Immusol Incorporated | Regulateurs de brca-1 et procedes d'utilisation |
AU2001245974A1 (en) | 2000-03-24 | 2001-10-08 | Millennium Pharmaceuticals, Inc. | 3714, 16742, 23546, and 13887 novel protein kinase molecules and uses therefor |
US20030198953A1 (en) * | 2000-03-30 | 2003-10-23 | Spytek Kimberly A. | Novel proteins and nucleic acids encoding same |
US7632929B2 (en) | 2000-04-20 | 2009-12-15 | The Board Of Trustees Of The University Of Arkansas | Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof |
AU5719501A (en) | 2000-04-25 | 2001-11-07 | Lexicon Genetics Inc | Novel human kinase proteins and polynucleotides encoding the same |
WO2001081586A2 (fr) * | 2000-04-26 | 2001-11-01 | Millennium Pharmaceuticals, Inc. | 21657, deshydrogenase humaine a chaine courte et ses utilisations |
US6808876B1 (en) | 2000-05-02 | 2004-10-26 | Immusol, Inc. | Cellular regulators of infectious agents and methods of use |
JP2003532412A (ja) * | 2000-05-12 | 2003-11-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 新規セリン−トレオニン・キナーゼ−4 |
WO2001090160A2 (fr) * | 2000-05-26 | 2001-11-29 | Bayer Aktiengesellschaft | Regulation de la serine/threonine kinase humaine analogue a p78 |
EP1158001B1 (fr) * | 2000-05-26 | 2007-11-14 | F. Hoffmann-La Roche Ag | Un acide nucléique produit excessivement dans des cellules tumorales humaines, une protéine codée par ledit acide nucléique et un procédé de diagnose de tumeurs |
DE10027170A1 (de) * | 2000-05-31 | 2001-12-13 | Schering Ag | Humanes PEM als Target für die Fertilitätskontrolle |
US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU6531101A (en) * | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001093805A2 (fr) * | 2000-06-02 | 2001-12-13 | The Brigham & Women's Hospital, Inc. | Fusion de genes jazf1 et jjaz1 dans des tumeurs stromatolithiques endometriales |
WO2001094385A2 (fr) * | 2000-06-05 | 2001-12-13 | Bayer Aktiengesellschaft | Regulation du recepteur couple a la proteine humaine g de type hm74 |
US6323016B1 (en) | 2000-06-09 | 2001-11-27 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
AU2001269766A1 (en) * | 2000-06-09 | 2001-12-24 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
JP2004513620A (ja) * | 2000-06-16 | 2004-05-13 | インサイト・ゲノミックス・インコーポレイテッド | プロテインホスファターゼ |
CA2648048A1 (fr) * | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese |
US7094587B2 (en) | 2000-06-27 | 2006-08-22 | Millennium Pharmaceuticals, Inc. | 16002 Molecules and uses therefor |
JP2004501623A (ja) * | 2000-06-27 | 2004-01-22 | キュラジェン コーポレイション | ポリヌクレオチドおよびそれによってコードされるポリペプチド |
AU2001271621A1 (en) | 2000-06-28 | 2002-01-08 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
WO2002002761A2 (fr) * | 2000-06-30 | 2002-01-10 | Millennium Pharmaceuticals, Inc. | 57658, nouvelle uridine kinase humaine et utilisations correspondantes |
WO2002004520A2 (fr) * | 2000-07-07 | 2002-01-17 | Incyte Genomics, Inc. | Transporteurs et canaux ioniques |
WO2002004510A2 (fr) * | 2000-07-07 | 2002-01-17 | Incyte Genomics, Inc. | Proteines liant le nucleotide guanine |
US20030171324A1 (en) * | 2000-07-18 | 2003-09-11 | Shyam Ramakrishnan | Regulation of human desc1-like serine protease |
WO2002006318A2 (fr) | 2000-07-18 | 2002-01-24 | Board Of Regents, The University Of Texas System | Procedes et compositions permettant de stabiliser des microtubules et des filaments intermediaires dans des cellules de muscle strie |
EP1354040A2 (fr) * | 2000-07-20 | 2003-10-22 | Genentech, Inc. | Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides |
AU8762901A (en) * | 2000-07-25 | 2002-02-05 | Merck Patent Gmbh | Novel protein containing ring finger domaine r1p4 |
AU2001277200A1 (en) * | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-cad protein and related reagents and methods of use thereof |
AU2001277202A1 (en) * | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-ras/rerg protein and related reagents and methods of use thereof |
US7335732B2 (en) | 2000-08-01 | 2008-02-26 | Genentech, Inc. | PRO9799 polypeptides |
EP1657254A3 (fr) * | 2000-08-01 | 2006-06-07 | Genentech, Inc. | Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer |
EP1315431A1 (fr) * | 2000-08-02 | 2003-06-04 | Millennium Pharmaceuticals, Inc. | Membre de la famille du facteur de liberation du gtp humain (15368) et ses utilisations |
US7402660B2 (en) | 2000-08-02 | 2008-07-22 | The Johns Hopkins University | Endothelial cell expression patterns |
WO2002012330A2 (fr) * | 2000-08-04 | 2002-02-14 | Zymogenetics, Inc. | Zzp1, proteine humaine secretee |
WO2002012285A2 (fr) * | 2000-08-10 | 2002-02-14 | Board Of Regents, The University Of Texas System | Suppresseur de tumeur car-1 |
AU9174501A (en) * | 2000-08-11 | 2002-02-25 | Merck Patent Gmbh | Novel mitogen activated kinase |
EP1326985A1 (fr) * | 2000-08-18 | 2003-07-16 | MERCK PATENT GmbH | Identification d'un gene d'acetyltransferase n-terminale humaine |
WO2002016586A2 (fr) * | 2000-08-21 | 2002-02-28 | Bristol-Myers Squibb Company | Nouvel homologue d'adenosine deaminase |
WO2002016587A2 (fr) * | 2000-08-21 | 2002-02-28 | Incyte Genomics, Inc. | Proteines associees aux microtubules et tubulines |
WO2002016579A2 (fr) * | 2000-08-24 | 2002-02-28 | Eli Lilly And Company | Acides nucleiques, vecteurs, cellules hotes, polypeptides et utilisations de ces derniers |
US7217799B2 (en) * | 2000-08-28 | 2007-05-15 | Agensys, Inc. | Antibodies that recognize the 85P1B3 protein useful in treatment and detection of cancer |
WO2002018568A2 (fr) * | 2000-08-28 | 2002-03-07 | Astrazeneca Ab | Molecules |
EP1313761A4 (fr) * | 2000-08-28 | 2005-01-26 | Human Genome Sciences Inc | 18 proteines humaines secretees |
WO2002018567A2 (fr) * | 2000-08-30 | 2002-03-07 | Bayer Aktiengesellschaft | Regulation d'enzyme humaine de type aminotransferase |
AU2001285908A1 (en) * | 2000-08-30 | 2002-03-13 | Bayer Aktiengesellschaft | Regulation of human aminotransferase-like enzyme |
WO2002018573A2 (fr) * | 2000-08-30 | 2002-03-07 | Millennium Pharmaceuticals, Inc. | Nouveau transporteur humain de sulfate: la proteine 54370, et utilisations associees |
US20020146800A1 (en) * | 2000-08-30 | 2002-10-10 | Curtis Rory A.J. | 48921, a novel human GTP releasing factor and uses therefor |
WO2002018582A2 (fr) * | 2000-08-31 | 2002-03-07 | Millennium Pharmaceuticals, Inc. | 62112, nouvelle deshydrogenase humaine et ses utilisations |
JP2004508043A (ja) | 2000-09-05 | 2004-03-18 | アムジェン インコーポレイテッド | Tnfレセプター様分子およびその使用 |
WO2002020754A2 (fr) * | 2000-09-05 | 2002-03-14 | Incyte Genomics, Inc. | Molecules utilisees a des fins diagnostiques et therapeutiques |
WO2002020765A2 (fr) * | 2000-09-08 | 2002-03-14 | Millennium Pharmaceuticals, Inc. | 38646, nouveau facteur d'echange de guanine nucleotide et ses utilisations |
US6372468B1 (en) | 2000-09-14 | 2002-04-16 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
US6391606B1 (en) * | 2000-09-14 | 2002-05-21 | Pe Corporation | Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
JP2004531203A (ja) * | 2000-10-05 | 2004-10-14 | キュラジェン コーポレイション | ヒトタンパク質、これらをコードするポリヌクレオチド、ならびにこれらの利用方法 |
AU2002211597A1 (en) * | 2000-10-11 | 2002-04-22 | Millennium Pharmaceuticals, Inc. | 8843, a human dual specificity phosphatase family member and uses therefor |
AU2002220613A1 (en) * | 2000-10-11 | 2002-04-22 | Bayer Aktiengesellschaft | Regulation of human cyclophilin-type peptidyl-prolyl cis-trans isomerase |
AU2002211715A1 (en) * | 2000-10-12 | 2002-04-22 | The Texas A And M University System | Nucleic acid sequences encoding cmg proteins cmg proteins and methods for their use |
WO2002030268A2 (fr) * | 2000-10-13 | 2002-04-18 | Eos Biotechnology, Inc. | Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate |
US6531297B2 (en) * | 2000-10-20 | 2003-03-11 | Applera Corporation | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
EP1385861A2 (fr) | 2000-10-25 | 2004-02-04 | Diadexus, Inc. | Compositions et techniques relatives a des genes et a des proteines specifiques du poumon |
AU2002220668A1 (en) * | 2000-10-31 | 2002-05-15 | Bayer Aktiengesellschaft | Regulation of human glutathione-s-transferase |
AU2002229011A1 (en) * | 2000-11-09 | 2002-05-21 | Glaxo Group Limited | Deaminase catalyzing the removal of the cyclopropyl moiety from abacavir-mp |
US6855517B2 (en) | 2000-11-20 | 2005-02-15 | Diadexus, Inc. | Compositions and methods relating to breast specific genes and proteins |
AU2001297765A1 (en) * | 2000-12-05 | 2002-10-21 | Incyte Genomics, Inc. | Ligases |
CA2430379A1 (fr) | 2000-12-07 | 2002-06-13 | Chiron Corporation | Retrovirus endogenes regules positivement dans le cancer de la prostate |
CA2429959A1 (fr) | 2000-12-07 | 2002-06-13 | Zymogenetics, Inc. | Proteine associee au complement adipocyte zacrp3x2 |
CA2439800A1 (fr) * | 2000-12-14 | 2002-06-20 | Pe Corporation (Ny) | Proteines kinases humaines isolees, molecules d'acide nucleique codant des proteines kinases humaines et utilisations associees |
US20020142376A1 (en) * | 2000-12-20 | 2002-10-03 | Gennady Merkulov | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
MXPA03005500A (es) | 2000-12-22 | 2004-04-20 | Bristol Myers Squibb Co | Proteina humana novedosa que contiene una repeticion rica en leucina, expresada predominantemente en intestino delgado, hlrrsi1. |
US7892730B2 (en) * | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
US6423521B1 (en) | 2000-12-28 | 2002-07-23 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
WO2002053591A1 (fr) * | 2000-12-30 | 2002-07-11 | Lion Bioscience Ag | Cofacteur de recepteur nucleaire mammalien cf12 et ses procedes d'utilisation |
AU2002236717A1 (en) * | 2001-01-08 | 2002-07-16 | Lexicon Genetics Incorporated | Human protease and polynucleotides encoding the same |
CA2436661A1 (fr) * | 2001-01-30 | 2002-08-08 | Regeneron Pharmaceuticals, Inc. | Nouvelles molecules d'acide nucleique et polypeptidiques |
EP1409536A2 (fr) * | 2001-02-12 | 2004-04-21 | Curagen Corporation | Proteines, polynucleotides codant pour lesdites proteines et methodes d'utilisation desdites proteines |
EP1637601A3 (fr) * | 2001-02-21 | 2006-03-29 | Curagen Corporation | Protéines , polynucléotides codant pour ces protéines et procédés d'utilisation |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
EP1434783A4 (fr) * | 2001-03-16 | 2006-06-07 | Lilly Co Eli | Proteines de mammiferes lp et reactifs associes |
US6913904B2 (en) * | 2001-03-27 | 2005-07-05 | Applera Corporation | Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof |
CA2443123A1 (fr) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers |
PT1573022E (pt) | 2001-04-10 | 2011-08-23 | Agensys Inc | Ácido nucleico e proteína correspondente intitulada 184p1e2, utilizadas para o tratamento e detecção de cancro |
EP1383922A4 (fr) | 2001-04-10 | 2005-03-30 | Agensys Inc | Acide nucleique et proteine correspondante intitule 158p3d2 utiles dans le traitement et la detection du cancer |
JP2004532030A (ja) * | 2001-04-24 | 2004-10-21 | イシス・イノベイション・リミテッド | 疾病用酵素とsnpマーカー |
KR20040015128A (ko) * | 2001-04-24 | 2004-02-18 | 오츠카 세이야쿠 가부시키가이샤 | 크론병 항체 결합성 펩티드 및 크론병의 검사 방법 |
JP4112374B2 (ja) | 2001-05-07 | 2008-07-02 | 塩野義製薬株式会社 | 血管新生マーカーとなるポリペプチドおよびそのdna |
AU2002314048A1 (en) * | 2001-05-09 | 2002-11-18 | Bayer Aktiengesellschaft | Regulation of human phosphatidic acid phosphatase type 2c-like protein |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
AU2002311535A1 (en) * | 2001-06-26 | 2003-01-08 | Decode Genetics Ehf. | Nucleic acids encoding protein kinases |
US20030120040A1 (en) | 2001-06-29 | 2003-06-26 | Genentech, Inc. | Secreted and Transmembrane polypeptides and nucleic acids encoding the same |
GB2399087A (en) * | 2001-08-02 | 2004-09-08 | Aeomica Inc | Human zinc finger containing gene MDZ7 |
WO2003031568A2 (fr) * | 2001-08-17 | 2003-04-17 | Incyte Genomics, Inc. | Molecules de signalisation intracellulaire |
US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
WO2003023063A1 (fr) * | 2001-09-07 | 2003-03-20 | Sankyo Company, Limited | Methode d'estimation du risque d'apparition de diabetes |
WO2003025175A2 (fr) * | 2001-09-17 | 2003-03-27 | Molecular Engines Laboratories | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments |
WO2003040369A2 (fr) * | 2001-09-17 | 2003-05-15 | Molecular Engines Laboratories | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments |
US7179627B2 (en) | 2001-09-28 | 2007-02-20 | Brigham Young University | Cyclooxygenase variants and methods of use |
EP1439225A4 (fr) | 2001-10-04 | 2005-10-26 | Kansai Tech Licensing Org Co | Promoteur du gene dr5 et promoteur du gene siah-1 |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
WO2003031607A1 (fr) * | 2001-10-10 | 2003-04-17 | Bayer Healthcare Ag | Regulation de deshydrogenase/reductase des chaines courtes humaine |
ATE364690T1 (de) | 2001-11-09 | 2007-07-15 | Proteologics Inc | Posh nukleinsäure, polypeptide und darauf bezogene verfahren |
US20050053940A1 (en) * | 2001-11-21 | 2005-03-10 | Joh-E Ikeda | Huntington's disease gene transcriptional factors |
US7151162B2 (en) | 2001-12-06 | 2006-12-19 | The University Of Children's Hospital Of Both Cantons Of Basel | Nuclear protein |
AU2002339697A1 (en) * | 2001-12-19 | 2003-06-30 | Genset S.A. | Gmg-5 polynucleotides and polypeptides and uses thereof |
JP2003245084A (ja) | 2001-12-20 | 2003-09-02 | Morinaga Milk Ind Co Ltd | 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途 |
DE10163467A1 (de) * | 2001-12-21 | 2003-11-27 | Axaron Bioscience Ag | Protein 24B2 und zugrundliegende DNA-Sequenz |
US6759222B2 (en) | 2002-01-02 | 2004-07-06 | Millennium Pharmaceuticals, Inc. | 14815, a human kinase family member and uses therefor |
WO2003057870A1 (fr) * | 2002-01-07 | 2003-07-17 | Bayer Healthcare Ag | Proteine humaine analogue a la phosphatase de l'acide phosphatidique de type 2 |
AU2003205611A1 (en) * | 2002-01-15 | 2003-07-30 | Medigene Ag | Dilated cardiomyopathy associated gene-2 (dcmag-2): a cytoplasmatic inducer of sarcomeric remodeling in cardiomyocytes |
AU2003235631A1 (en) * | 2002-01-15 | 2003-07-30 | Bayer Aktiengesellschaft | Human subtilisin/kexin-like convertase |
JPWO2003062429A1 (ja) * | 2002-01-23 | 2005-05-26 | 山之内製薬株式会社 | 新規セリンプロテアーゼ |
EP1338609A1 (fr) * | 2002-02-21 | 2003-08-27 | MEMOREC Stoffel GmbH-Medizinisch-Molekulare Entwicklung, Köln | Un outre récepteur KDR et son utilisation |
EP1497311A2 (fr) * | 2002-03-05 | 2005-01-19 | Applera Corporation | Proteines transporteuses humaines isolees, molecules d'acide nucleique codant celles-ci, et utilisations associees |
GB2388113A (en) * | 2002-03-06 | 2003-11-05 | Oxford Glycosciences | B-cell malignancy-associated protein |
ES2685702T3 (es) | 2002-03-13 | 2018-10-10 | Genomic Health, Inc. | Obtención de perfil de expresión génica en tejidos tumorales biopsiados |
AU2003220913A1 (en) * | 2002-03-19 | 2003-09-29 | Tanabe Seiyaku Co., Ltd. | Novel g protein-coupled recepotrs and genes thereof |
US7527935B2 (en) | 2002-03-19 | 2009-05-05 | Mitsubishi Tanabe Pharma Corporation | G-protein coupled receptor having eicosanoid as ligand and gene thereof |
GB0206684D0 (en) * | 2002-03-21 | 2002-05-01 | Babraham Inst | Novel proteins |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
CA2413475C (fr) | 2002-04-25 | 2010-07-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Expression de zap-70 en tant que marqueur de la leucemie chronique lymphoide/du lymphome a petits lymphocytes (lcl/lpl) |
JP2004041003A (ja) * | 2002-05-17 | 2004-02-12 | Takeda Chem Ind Ltd | 新規タンパク質、そのdnaおよびその用途 |
EP2275118A3 (fr) | 2002-05-29 | 2011-10-19 | DeveloGen Aktiengesellschaft | Proteines specifiques du pancreas |
WO2003101401A2 (fr) | 2002-06-03 | 2003-12-11 | Chiron Corporation | Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas |
EP2233572A3 (fr) * | 2002-06-06 | 2011-01-12 | Oncotherapy Science, Inc. | Gènes et polypeptides en rapport avec les cancers du colon chez l'homme |
EP1532161B1 (fr) | 2002-06-13 | 2012-02-15 | Novartis Vaccines and Diagnostics, Inc. | Vecteurs pour l'expression de polypeptides hml-2 |
US20060172296A1 (en) * | 2002-07-22 | 2006-08-03 | Masahiro Takeuchi | Novel gene associated with rheumatoid arthritis |
CA2495177C (fr) | 2002-08-14 | 2014-01-21 | National Institute Of Advanced Industrial Science And Technology | Nouvelles n-acetylgalactosamine transferases et acides nucleiques codant ces transferases |
AU2003243151A1 (en) * | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
WO2004018518A1 (fr) * | 2002-08-23 | 2004-03-04 | Japan Science And Technology Agency | Peptides antigeniques de tumeur cancereuse solide humains, polynucleotides codant pour ceux-ci et utilisation de ceux-ci |
EP1540014A2 (fr) * | 2002-08-27 | 2005-06-15 | Epigenomics AG | Procede et acides nucleiques servant a l'analyse de troubles lies a la proliferation des cellules mammaires |
US7452969B2 (en) | 2002-08-30 | 2008-11-18 | Licentia Ltd | Neurotrophic factor protein and uses thereof |
US7601826B2 (en) * | 2002-09-30 | 2009-10-13 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human pancreatic cancers |
EP1552310A2 (fr) * | 2002-10-17 | 2005-07-13 | EVOTEC Neurosciences GmbH | L'utilisation de la proteine et du gene de la nicotinamide mononucleotide adenylyltransferase 2 (nmnat-2) pour le diagnostique et la therapie des maladies neurodegeneratives |
AU2002952216A0 (en) * | 2002-10-23 | 2002-11-07 | The Walter And Eliza Hall Institute Of Medical Research | Novel therapeutic molecules |
EP1570080A4 (fr) | 2002-11-15 | 2006-03-01 | Genomic Health Inc | Etablissement de profils d'expressions genetique du cancer a recepteur de facteur de croissance epidermique positif |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
AU2003287764B2 (en) * | 2002-12-13 | 2010-01-21 | The Walter And Eliza Hall Institute Of Medical Research | A novel phosphoprotein |
AU2002953341A0 (en) * | 2002-12-13 | 2003-01-09 | The Walter And Eliza Hall Institute Of Medical Research | A novel phosphoprotein |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
US7326768B2 (en) | 2003-02-05 | 2008-02-05 | Juan Saus | Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders |
EP1445614A1 (fr) * | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Méthodes d'évaluation in vitro de l'état de progression d'un virus HIV chez un individu |
US7074891B2 (en) * | 2003-02-07 | 2006-07-11 | Posco | Leukocyte stimulating peptides |
ATE412779T1 (de) | 2003-02-20 | 2008-11-15 | Genomic Health Inc | Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression |
CA2517953A1 (fr) * | 2003-03-04 | 2004-09-16 | Astellas Pharma Inc. | Nouveau gene associe a des conditions fibreuses |
SI1606409T1 (sl) | 2003-03-19 | 2011-01-31 | Biogen Idec Inc | Vezavni protein receptorja Nogo |
ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
EP2775000B1 (fr) | 2003-06-24 | 2016-11-09 | Genomic Health, Inc. | Prédiction de probabilité de récurrence de cancer |
CA2531967C (fr) | 2003-07-10 | 2013-07-16 | Genomic Health, Inc. | Algorithme de profile d'expression et test du pronostic du cancer |
JP4643450B2 (ja) | 2003-08-08 | 2011-03-02 | 株式会社ペルセウスプロテオミクス | 癌高発現遺伝子 |
US20050136434A1 (en) * | 2003-08-12 | 2005-06-23 | Mai Xu | Isolated heat-inducible cell surface protein and hyperthermia-based tumor immunotargeting therapy |
US20070178458A1 (en) * | 2003-09-05 | 2007-08-02 | O'brien Philippa | Methods of diagnosis and prognosis of ovarian cancer II |
WO2005026314A2 (fr) * | 2003-09-10 | 2005-03-24 | Japan Science And Technology Agency | Groupe de genes exprimes de facon differentielle dans des cellules de sang peripherique ainsi que procede de diagnostic et procede d'analyse mettant en oeuvre ce groupe |
EP1667712B1 (fr) * | 2003-10-02 | 2010-07-21 | GlaxoSmithKline Biologicals S.A. | Antigenes de b. pertussis et leur utilisation dans la vaccination |
CA2541006C (fr) | 2003-10-03 | 2015-02-17 | Brigham And Women's Hospital | Ligands de tim-3 et methodes associees |
WO2005040791A2 (fr) * | 2003-10-21 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr) |
US20050255560A1 (en) * | 2003-11-21 | 2005-11-17 | Zeren Gao | Ztnf11, a tumor necrosis factor |
KR20070000438A (ko) | 2003-12-23 | 2007-01-02 | 게노믹 헬쓰, 인코포레이티드 | 단편화 rna의 범용적 증폭 |
US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
EP2497836B1 (fr) * | 2004-03-02 | 2015-01-14 | The Johns Hopkins University | Mutations du gène PIK3CA dans les cancers humains |
TW200539890A (en) | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
WO2005090569A1 (fr) * | 2004-03-24 | 2005-09-29 | The Council Of The Queensland Institute Of Medical Research | Cancer et acides nucleiques et proteines de testicule vsm1 et vsm2, et leurs utilisations |
AU2005229434B2 (en) | 2004-03-30 | 2010-09-30 | Nsgene A/S | Therapeutic use of a growth factor, NsG33 |
WO2005100606A2 (fr) | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Marqueurs d'expression genique permettant de predire la reponse a la chimiotherapie |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
WO2005118832A2 (fr) * | 2004-06-01 | 2005-12-15 | Bayer Healthcare Ag | Agents diagnostiques et therapeutiques pour des maladies associees a une proteine de type kinase regulee par serum/glucocorticoide (sgkl) |
EP1776136B1 (fr) | 2004-06-24 | 2012-10-03 | Biogen Idec MA Inc. | Traitement d'etats pathologiques impliquant la demyelinisation |
US7587279B2 (en) | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
US7985831B2 (en) * | 2004-08-05 | 2011-07-26 | Toagosei Co., Ltd. | Crohn's disease antibody epitope peptide and reagent for testing Crohn's disease |
ES2778851T3 (es) | 2004-11-05 | 2020-08-12 | Genomic Health Inc | Predicción de la respuesta a la quimioterapia mediante el uso de marcadores de expresión génica |
ES2384107T3 (es) | 2004-11-05 | 2012-06-29 | Genomic Health, Inc. | Indicadores moleculares de pronóstico de cáncer de mama y predicción de la respuesta al tratamiento |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
KR101027427B1 (ko) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체 |
CA2608315C (fr) * | 2005-05-13 | 2014-08-05 | Centre National De La Recherche Scientifique | Utilisation de nouveau codage genique pour nouvel element de la famille mcm2-8 dans les compositions pharmaceutiques |
EP2478917A1 (fr) | 2005-07-08 | 2012-07-25 | Biogen Idec MA Inc. | Anticorps Sp35 et utilisations associées |
EP1907589A4 (fr) * | 2005-07-26 | 2010-11-24 | Siemens Healthcare Diagnostics | Polymorphismes de nucleotides uniques a susceptibilite par rapport a une maladie cardio-vasculaire |
WO2007037601A1 (fr) * | 2005-09-28 | 2007-04-05 | Knu-Industry Cooperation Foundation | Polypeptide inhibant la transmigration de leucocytes ou la croissance et/ou la métastase de cellules cancéreuses, et une protéine de fusion de celui-ci |
EP1790664A1 (fr) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Anticorps monoclonaux contre claudin-18 pour le traitement du cancer |
DE602005023550D1 (de) | 2005-12-14 | 2010-10-21 | Licentia Ltd | Verwendungen eines neurotrophischen Faktors |
KR20090111307A (ko) * | 2006-07-03 | 2009-10-26 | 엑손히트 써라퓨틱스 에스에이 | 전립선 특이적 전사물 및 전립선암의 치료 및 진단에 사용되는 이의 용도 |
WO2008030559A2 (fr) * | 2006-09-08 | 2008-03-13 | Corixa Corporation | Procédés, compositions, et kits de détection et de surveillance d'un cancer du colon |
US8999634B2 (en) * | 2007-04-27 | 2015-04-07 | Quest Diagnostics Investments Incorporated | Nucleic acid detection combining amplification with fragmentation |
GB0805159D0 (en) | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
UA101810C2 (ru) | 2007-07-27 | 2013-05-13 | Имматикс Биотекнолоджис Гмбх | Новые методы иммунотерапии в лечении нейрональных опухолей и опухолей головного мозга |
US7863021B2 (en) * | 2007-09-05 | 2011-01-04 | Celera Corporation | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof |
WO2009034661A1 (fr) * | 2007-09-12 | 2009-03-19 | Toppan Printing Co., Ltd. | Procédé de diagnostic et induction d'une résistance à un virus |
JP2011500047A (ja) | 2007-10-17 | 2011-01-06 | ウニベルシダ・ドゥ・コルドバ | オルタナティブプロセシングにより産生されるヒトソマトスタチン受容体タイプ5のアイソフォーム、およびpcrによるその検出のためのオリゴヌクレオチドペア |
EP2808343B8 (fr) | 2007-12-26 | 2020-01-15 | Xencor, Inc. | Variantes Fc avec liaison altérée en FcRn |
GB0803352D0 (en) * | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
WO2009115612A1 (fr) * | 2008-03-21 | 2009-09-24 | Universiteit Hasselt | Biomarqueurs de la polyarthrite rhumatoïde |
JP2011527572A (ja) | 2008-07-09 | 2011-11-04 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Lingo抗体または断片を含む組成物 |
JP5616888B2 (ja) | 2008-07-24 | 2014-10-29 | エヌエスジーン・アクティーゼルスカブNsGene A/S | 成長因子metrnlの治療的使用 |
DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
WO2010057069A1 (fr) | 2008-11-14 | 2010-05-20 | Gen-Probe Incorporated | Compositions, kits et procédés pour la détection d’acide nucléique de campylobacter |
WO2010062960A2 (fr) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | Méthodes de détermination d'une réceptivité à une thérapie par anti-tnfα lors d’une maladie intestinale inflammatoire |
WO2010066018A1 (fr) * | 2008-12-09 | 2010-06-17 | Alethia Biotherapeutics Inc. | Nouveau variant rétroviral endogène humain d’erv3 et utilisations de celui-ci pour diagnostiquer le cancer des ovaires |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
CA2787940C (fr) | 2010-01-27 | 2020-01-07 | Massachusetts Institute Of Technology | Agents polypeptidiques techniques pour la neutralisation de la grippe a large spectre ciblee |
TWI651096B (zh) | 2010-09-29 | 2019-02-21 | 美商艾澤西公司 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
KR101886029B1 (ko) | 2010-10-01 | 2018-08-07 | 호바 세라퓨틱스 에이피에스 | 무해자극통증, 통각과민증, 자발통증 및 헛통증의 치료를 위한 메테오린의 용도 |
US9168284B2 (en) | 2010-12-14 | 2015-10-27 | Sveinbjorn Gizurarson | Biological activity of placental protein 13 |
CN107596346A (zh) | 2011-09-05 | 2018-01-19 | 霍巴治疗公司 | 异常性疼痛、痛觉过敏、自发性疼痛、和幻痛的治疗 |
WO2013068445A1 (fr) * | 2011-11-09 | 2013-05-16 | Sanofi | Diacylglycérol lipase et applications associées |
MY174248A (en) | 2012-04-30 | 2020-04-01 | Biocon Ltd | Targeted/immunomodulatory fusion proteins and methods for making same |
WO2013167153A1 (fr) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Anticorps utiles dans le diagnostic du cancer |
JP2015518829A (ja) | 2012-05-14 | 2015-07-06 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 運動ニューロンに関する状態の処置のためのlingo−2アンタゴニスト |
WO2013174404A1 (fr) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer |
CN105073776B (zh) | 2012-11-13 | 2019-04-12 | 拜恩科技股份公司 | 用于治疗表达紧密连接蛋白的癌症疾病的制剂 |
WO2014127785A1 (fr) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer |
US9023353B2 (en) * | 2013-03-13 | 2015-05-05 | The Board Of Trustees Of The University Of Arkansas | Anti-(+)—methamphetamine monoclonal antibodies |
WO2014146672A1 (fr) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer |
MX2015013703A (es) | 2013-03-27 | 2016-08-11 | Cedars Sinai Medical Center | Mitigacion e inversion de la fibrosis e inflamacion mediante la inhibicion de la funcion de tl1a y vias de señalizacion relacionadas. |
JP7019233B2 (ja) | 2013-07-11 | 2022-02-15 | モデルナティエックス インコーポレイテッド | CRISPR関連タンパク質をコードする合成ポリヌクレオチドおよび合成sgRNAを含む組成物ならびに使用方法 |
WO2015010108A1 (fr) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature de la voie de signalisation de tl1a (tnfsf15) |
RU2020106752A (ru) | 2013-09-25 | 2020-03-11 | Сайтомкс Терапьютикс, Инк. | Субстраты матриксной металлопротеиназы и другие расщепляемые фрагменты и способы их использования |
JP6558699B2 (ja) | 2013-10-01 | 2019-08-14 | 国立大学法人三重大学 | 抗原提示を促進するエピトープ間配列を含むt細胞誘導ワクチン |
EP4176896A1 (fr) | 2014-01-31 | 2023-05-10 | Cytomx Therapeutics Inc. | Substrats d'activateur de matriptase et du plasminogène u et d'autres fractions clivables et leurs procédés d'utilisation |
WO2016112270A1 (fr) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation |
MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
US11124766B2 (en) * | 2015-06-12 | 2021-09-21 | Emory University | Growth and survival compositions for cells capable of producing antibodies and methods related thereto |
CN108138198B (zh) * | 2015-09-04 | 2022-10-28 | 合成基因组股份有限公司 | 为提高的产率而改造的微生物 |
KR20220153109A (ko) | 2016-03-17 | 2022-11-17 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
WO2017172941A2 (fr) * | 2016-03-29 | 2017-10-05 | Berz David | Modulation de l'entretien structural de l'expression du chromosome-1 |
US9611297B1 (en) | 2016-08-26 | 2017-04-04 | Thrasos Therapeutics Inc. | Compositions and methods for the treatment of cast nephropathy and related conditions |
US11125757B2 (en) | 2017-05-26 | 2021-09-21 | Emory University | Methods of culturing and characterizing antibody secreting cells |
EP3508499A1 (fr) | 2018-01-08 | 2019-07-10 | iOmx Therapeutics AG | Anticorps ciblant et d'autres modulateurs d'un gène d'immunoglobuline associé à une résistance contre des réponses immunitaires antitumorales et leurs utilisations |
CN114401992A (zh) | 2019-07-05 | 2022-04-26 | 艾欧麦克斯治疗股份公司 | 结合igsf11(vsig3)的igc2的抗体及其用途 |
WO2021083958A1 (fr) * | 2019-10-29 | 2021-05-06 | Specialites Pet Food | Nouveaux peptides induisant la satiété |
US20230212243A1 (en) * | 2020-05-12 | 2023-07-06 | Institut Curie | Neoantigenic Epitopes Associated with SF3B1 Mutations |
US20240010720A1 (en) | 2020-07-06 | 2024-01-11 | Iomx Therapeutics Ag | Antibodies binding igv of igsf11 (vsig3) and uses thereof |
JP2024504690A (ja) * | 2021-01-21 | 2024-02-01 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | 治療における使用のためのt細胞 |
JP2024509376A (ja) * | 2021-02-18 | 2024-03-01 | ベレン セラピューティクス ピー.ビー.シー. | 家族性ヘテロ接合型及びホモ接合型高コレステロール血症のシクロデキストリンによる治療方法 |
WO2023225602A1 (fr) * | 2022-05-20 | 2023-11-23 | Medikine, Inc. | Polypeptides de liaison au récepteur de l'interleukine-18 et leurs utilisations |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4446240A (en) * | 1981-01-30 | 1984-05-01 | Nerenberg Samuel T | Pancreas specific protein systems |
US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
US6080540A (en) * | 1990-04-20 | 2000-06-27 | Cold Spring Harbor Laboratory | Cloning of mammalian genes in microbial organisms and methods for pharmacological screening |
AU656350B2 (en) * | 1990-11-26 | 1995-02-02 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Cell stress transcriptional factors |
US5721352A (en) * | 1991-02-19 | 1998-02-24 | University Of Florida Research Foundation | Entomopoxvirus expression system |
US5840870A (en) * | 1995-12-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Polynucleotides PANC1A and PANC1B associated with pancreatic cancer |
WO1997007827A1 (fr) * | 1995-08-22 | 1997-03-06 | Thomas Jefferson University | Gab1, QUI EST UNE PROTEINE SE LIANT A Grb2, ET COMPOSITIONS POUR PRODUIRE ET UTILISER CETTE PROTEINE |
JP3462313B2 (ja) * | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体dna及び変異型ウリカーゼの製造法 |
US5998165A (en) * | 1995-12-29 | 1999-12-07 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a protein associated with pancreatic cancer |
AU721105B2 (en) * | 1996-04-29 | 2000-06-22 | Johns Hopkins University School Of Medicine, The | Mammalian regulator of nonsense-mediated RNA decay |
US6500934B1 (en) * | 1996-07-24 | 2002-12-31 | Michael Rush Lerner | Bivalent agonists for G-protein coupled receptors |
US5976834A (en) * | 1997-01-09 | 1999-11-02 | Smithkline Beecham Corporation | cDNA clone HNFJD15 that encodes a novel human 7-transmembrane receptor |
US5925521A (en) * | 1997-03-31 | 1999-07-20 | Incyte Pharmaceuticals, Inc. | Human serine carboxypeptidase |
CA2232743A1 (fr) * | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | Tl5, homologue tnf |
JP2001519666A (ja) * | 1997-04-10 | 2001-10-23 | ジェネティックス・インスチチュート・インコーポレーテッド | 分泌発現配列タグ(sESTs) |
IT1291110B1 (it) * | 1997-04-15 | 1998-12-29 | Istituto Europ Di Oncologia S | Interattori intracellulari e specificita' di legame del dominio eh |
US5948641A (en) * | 1997-05-29 | 1999-09-07 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a metal response element binding protein |
IL133315A0 (en) * | 1997-06-06 | 2001-04-30 | Regeneron Pharma | Ntn-2 member of tnf ligand family |
AU9484398A (en) * | 1997-09-17 | 1999-04-05 | Genentech Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
US5932442A (en) * | 1997-09-23 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Human regulatory molecules |
US5972660A (en) * | 1997-10-22 | 1999-10-26 | Incyte Pharmaceuticals, Inc. | Human hydroxypyruvate reductase |
DE19818598A1 (de) * | 1998-04-19 | 1999-10-21 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Pankreasnormalgewebe |
CN1158386C (zh) * | 1998-04-29 | 2004-07-21 | 吉尼西斯研究及发展有限公司 | 从皮肤细胞中分离的多核苷酸及其使用方法 |
US6262249B1 (en) * | 1998-06-23 | 2001-07-17 | Chiron Corporation | Pancreatic cancer genes |
CA2296792A1 (fr) * | 1999-02-26 | 2000-08-26 | Genset S.A. | Sequences marqueurs exprimees et proteines humaines codees |
-
2001
- 2001-01-17 WO PCT/US2001/001321 patent/WO2001055312A2/fr active Search and Examination
- 2001-01-17 AU AU2001241409A patent/AU2001241409A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001312 patent/WO2001054733A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001345 patent/WO2001055325A2/fr active Search and Examination
- 2001-01-17 CA CA002395724A patent/CA2395724A1/fr active Pending
- 2001-01-17 CA CA002395885A patent/CA2395885A1/fr not_active Withdrawn
- 2001-01-17 CA CA002392398A patent/CA2392398A1/fr not_active Abandoned
- 2001-01-17 CA CA002397839A patent/CA2397839A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001357 patent/WO2001055208A1/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001332 patent/WO2001055318A2/fr active Search and Examination
- 2001-01-17 AU AU2001241410A patent/AU2001241410A1/en not_active Abandoned
- 2001-01-17 CA CA002393002A patent/CA2393002A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001313 patent/WO2001055200A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001359 patent/WO2001055328A2/fr active Application Filing
- 2001-01-17 WO PCT/US2001/001341 patent/WO2001055322A2/fr active Search and Examination
- 2001-01-17 CA CA002395693A patent/CA2395693A1/fr active Pending
- 2001-01-17 CA CA002394039A patent/CA2394039A1/fr not_active Abandoned
- 2001-01-17 WO PCT/US2001/001342 patent/WO2001059064A2/fr active Search and Examination
- 2001-01-17 CA CA002395858A patent/CA2395858A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001335 patent/WO2001055319A2/fr active Search and Examination
- 2001-01-17 AU AU2001241407A patent/AU2001241407A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001325 patent/WO2001055202A1/fr active Search and Examination
- 2001-01-17 CA CA002395787A patent/CA2395787A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395849A patent/CA2395849A1/fr active Pending
- 2001-01-17 CA CA002395666A patent/CA2395666A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395671A patent/CA2395671A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395734A patent/CA2395734A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001356 patent/WO2001055173A2/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001315 patent/WO2001055311A2/fr active Search and Examination
- 2001-01-17 AU AU2001241408A patent/AU2001241408A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001309 patent/WO2001055308A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001333 patent/WO2001055448A1/fr active Search and Examination
- 2001-01-17 AU AU2001241413A patent/AU2001241413A1/en not_active Abandoned
- 2001-01-17 CA CA002395699A patent/CA2395699A1/fr active Pending
- 2001-01-17 WO PCT/US2001/001355 patent/WO2001055207A1/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001324 patent/WO2001055314A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001314 patent/WO2001055310A2/fr active Search and Examination
- 2001-01-17 CA CA002392757A patent/CA2392757A1/fr not_active Abandoned
- 2001-01-17 WO PCT/US2001/001352 patent/WO2001055327A2/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001310 patent/WO2001055387A1/fr active Search and Examination
- 2001-01-17 CA CA002392450A patent/CA2392450A1/fr not_active Abandoned
- 2001-01-17 WO PCT/US2001/001336 patent/WO2001055204A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001311 patent/WO2001055309A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001343 patent/WO2001055323A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001338 patent/WO2001055367A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001326 patent/WO2001055315A2/fr active Search and Examination
- 2001-01-17 CA CA002394841A patent/CA2394841A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001239 patent/WO2001055301A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001322 patent/WO2001055343A1/fr active Search and Examination
- 2001-01-17 CA CA002395178A patent/CA2395178A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001308 patent/WO2001055364A2/fr active Search and Examination
- 2001-01-17 AU AU2001241406A patent/AU2001241406A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001349 patent/WO2001054474A2/fr active Search and Examination
- 2001-01-17 CA CA002395729A patent/CA2395729A1/fr active Pending
- 2001-01-17 CA CA002395403A patent/CA2395403A1/fr not_active Withdrawn
- 2001-01-17 CA CA002397407A patent/CA2397407A1/fr not_active Withdrawn
- 2001-01-17 CA CA002393652A patent/CA2393652A1/fr not_active Withdrawn
- 2001-01-17 CA CA002392751A patent/CA2392751A1/fr not_active Abandoned
- 2001-01-17 CA CA002392438A patent/CA2392438A1/fr not_active Abandoned
- 2001-01-17 WO PCT/US2001/001306 patent/WO2001055307A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001348 patent/WO2001055368A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001350 patent/WO2001055350A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001316 patent/WO2001054473A2/fr active Search and Examination
- 2001-01-17 CA CA002395816A patent/CA2395816A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001240 patent/WO2001055302A2/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001328 patent/WO2001055316A2/fr active Search and Examination
- 2001-01-17 AU AU2001241415A patent/AU2001241415A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001317 patent/WO2001055201A1/fr active Search and Examination
- 2001-01-17 CA CA002395827A patent/CA2395827A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001330 patent/WO2001055447A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001344 patent/WO2001055324A2/fr active Search and Examination
- 2001-01-17 CA CA002395872A patent/CA2395872A1/fr not_active Withdrawn
- 2001-01-17 CA CA002393912A patent/CA2393912A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241416A patent/AU2001241416A1/en not_active Abandoned
- 2001-01-17 CA CA002395654A patent/CA2395654A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001302 patent/WO2001055304A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001337 patent/WO2001055205A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001351 patent/WO2001055355A1/fr active Search and Examination
- 2001-01-17 CA CA002393618A patent/CA2393618A1/fr not_active Abandoned
- 2001-01-17 CA CA002395398A patent/CA2395398A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001301 patent/WO2001055303A2/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001353 patent/WO2001055206A1/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001339 patent/WO2001055320A2/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001358 patent/WO2001055163A1/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001340 patent/WO2001055321A2/fr active Search and Examination
- 2001-01-17 CA CA002398877A patent/CA2398877A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395295A patent/CA2395295A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241417A patent/AU2001241417A1/en not_active Abandoned
- 2001-01-17 AU AU2001250770A patent/AU2001250770A1/en not_active Abandoned
- 2001-01-17 AU AU2001241414A patent/AU2001241414A1/en not_active Abandoned
- 2001-01-17 CA CA002398411A patent/CA2398411A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001327 patent/WO2001055203A1/fr active Search and Examination
- 2001-01-17 AU AU2001241412A patent/AU2001241412A1/en not_active Abandoned
- 2001-01-17 CA CA002395738A patent/CA2395738A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241418A patent/AU2001241418A1/en not_active Abandoned
- 2001-01-17 AU AU2001241405A patent/AU2001241405A1/en not_active Abandoned
- 2001-01-17 CA CA002392428A patent/CA2392428A1/fr not_active Abandoned
- 2001-01-17 CA CA002392422A patent/CA2392422A1/fr not_active Abandoned
- 2001-01-17 WO PCT/US2001/001354 patent/WO2001057182A2/fr not_active Application Discontinuation
- 2001-02-05 AU AU4313701A patent/AU4313701A/xx active Pending
- 2001-02-08 AU AU4141101A patent/AU4141101A/xx active Pending
Non-Patent Citations (1)
Title |
---|
DATABASE GENBANK [Online] MAHAIRAS G.G. ET AL.: 'Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome', XP002944493 Database accession no. AQ453387 & PROC. NATL. ACAD. SCI. USA vol. 96, no. 17, 1999, pages 9739 - 9744 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1157038A4 (fr) * | 1999-02-26 | 2005-01-19 | Smithkline Beecham Corp | Clonage du recepteur 7tm (axor 17) du type p2y |
US6893818B1 (en) | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
US7771968B2 (en) | 1999-10-28 | 2010-08-10 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
US7928212B2 (en) | 1999-10-28 | 2011-04-19 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
US7838491B2 (en) | 2001-11-14 | 2010-11-23 | Northwestern University | Self-assembly and mineralization of peptide-amphiphile nanofibers |
US8063014B2 (en) | 2002-02-15 | 2011-11-22 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
US8124583B2 (en) | 2002-11-12 | 2012-02-28 | Northwestern University | Composition and method for self-assembly and mineralization of peptide-amphiphiles |
US8138140B2 (en) * | 2003-12-05 | 2012-03-20 | Northwestern University | Self-assembling peptide amphiphiles and related methods for growth factor delivery |
US8580923B2 (en) | 2003-12-05 | 2013-11-12 | Northwestern University | Self-assembling peptide amphiphiles and related methods for growth factor delivery |
US7851445B2 (en) | 2005-03-04 | 2010-12-14 | Northwestern University | Angiogenic heparin-binding epitopes, peptide amphiphiles, self-assembled compositions and related methods of use |
US8076295B2 (en) | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
US8450271B2 (en) | 2009-04-13 | 2013-05-28 | Northwestern University | Peptide-based scaffolds for cartilage regeneration and methods for their use |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001055302A2 (fr) | Acides nucleiques, proteines et anticorps | |
WO2002000677A1 (fr) | Acides nucleiques, proteines et anticorps | |
WO2001090304A2 (fr) | Acides nucleiques, proteines et anticorps | |
WO2001055317A2 (fr) | Acides nucleiques, proteines et anticorps | |
EP1392817A2 (fr) | Proteines secretees par l'etre humain | |
WO2001055326A2 (fr) | Acides nucleiques, proteines et anticorps | |
WO2001055441A2 (fr) | Acides nucléiques, protéines et anticorps | |
EP1370651A1 (fr) | 70 proteines humaines secretees | |
EP1252289A2 (fr) | Acides nucleiques, proteines et anticorps | |
WO2001055167A1 (fr) | Acides nucleiques, proteines et anticorps | |
WO2002057420A2 (fr) | 50 proteines secretees humaines | |
WO2001055162A1 (fr) | Acides nucleiques, proteines et anticorps | |
WO2001055313A2 (fr) | Acides nucleiques, proteines et anticorps | |
EP1252337A2 (fr) | Acides nucleiques, proteines et anticorps | |
EP1254217A2 (fr) | Acides nucl iques, prot ines et anticorps | |
WO2001055329A2 (fr) | Acides nucleiques, proteines et anticorps | |
EP1261742A2 (fr) | Acides nucleiques, proteines et anticorps |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 31/2001 UNDER "PUBLISHED", ADD "WITH SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU." |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2394039 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001910326 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001910326 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001910326 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |